Clinical Trial Update: Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL [Phase 1, Phase 2]

View source ↗

Summary

Dose-escalation early-stage trial assessing safety of PBCAR20A in relapsed/refractory Non-Hodgkin's Lymphoma and relapsed/refractory Chronic Lymphoid Leukemia/S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Leukemia Lymphocytic Chronic
• Lymphoid Leukemia
• Lymphoma Non-hodgkin
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• PBCAR20A

Snippet

Sponsor: Precision BioSciences, Inc. | Conditions: Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-01-31